Aug 26, 2026 08:32PM
Aug 16, 2026 08:35PM
Aug 16, 2026 08:35PM
Jul 29, 2026 08:57PM
Jul 13, 2026 08:35PM
Jul 13, 2026 08:35PM
Jul 9, 2026 08:30PM Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
Jun 30, 2026 08:38PM
Jun 24, 2026 08:59PM
Apr 28, 2026 08:53PM
Apr 28, 2026 08:53PM
Apr 14, 2026 08:11PM
Apr 14, 2026 08:10PM
Apr 10, 2026 04:09PM Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION
Apr 8, 2026 09:07AM
Apr 7, 2026 11:35PM
Mar 17, 2026 07:19PM
Mar 11, 2026 07:21PM
Feb 26, 2026 07:42PM
Feb 11, 2026 06:27PM
Jan 28, 2026 06:54PM Ryoncil® Net Revenues Increase for the Quarter to US$30M
Jan 26, 2026 06:45PM
Jan 18, 2026 07:01PM
Jan 8, 2026 06:46PM
Jan 1, 2026 06:02PM
Jan 1, 2026 06:02PM
Dec 29, 2025 06:57PM
Dec 11, 2025 06:22PM Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD
Dec 3, 2025 06:10PM
Nov 24, 2025 06:39PM
Nov 20, 2025 06:32PM
Nov 4, 2025 06:40PM
Oct 19, 2025 07:48PM
Oct 6, 2025 07:24PM
Oct 2, 2025 09:04PM Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access
Sep 26, 2025 01:49AM
Sep 14, 2025 09:18PM
Sep 3, 2025 09:47PM
Aug 28, 2025 08:24PM
Jul 17, 2025 08:38PM
Jun 30, 2025 08:36PM
Jun 11, 2025 09:24PM Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
May 14, 2025 11:36PM
May 14, 2025 10:57PM
Apr 29, 2025 08:53PM
Apr 28, 2025 07:44PM
Apr 3, 2025 06:58PM
Apr 2, 2025 07:15PM
Mar 30, 2025 07:39PM First Three Children to Commence Treatment With Ryoncil®
Mar 13, 2025 07:42PM

329,890 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All